Targeting PTPN14: P1-12 and GLT-135 as Potential TherapeuticAgents for GBM

Target Name: PTPN14

NCBI ID: G5784

PTPN14

Targeting PTPN14: P1-12 and GLT-135 as Potential TherapeuticAgents for GBM

Glioblastoma multiforme (GBM) is a type of brain cancer that is characterized by the rapid and uncontrolled growth of cells that form a tumor. Despite advances in treatment, the survival rate for GBM remains high, with a five-year survival rate of only around 50%. Therefore, there is a need for new and effective treatments to improve outcomes for patients.

One potential drug target for GBM is PTPN14 (MGC126803), a gene that has been identified as a potential therapeutic target for GBM. PTPN14 is a protein that is expressed in a variety of tissues, including brain, and has been shown to play a role in the development and progression of GBM.

Targeting PTPN14

PTPN14 is a transmembrane protein that is expressed in the brain and has been shown to play a role in the development and progression of GBM. GBM tumors express high levels of PTPN14, and downregulation of PTPN14 has been shown to inhibit the growth and survival of GBM tumors.

One potential way to target PTPN14 is through the use of small molecules, such as inhibitors or modulators, that can reduce the expression or activity of PTPN14. One such small molecule is called P1-12, which is a specific inhibitor of PTPN14 that has been shown to inhibit the growth of GBM tumors in cell culture and animal models.

Another potential way to target PTPN14 is through the use of monoclonal antibodies (MCAs), which are laboratory-produced antibodies that can be used to target specific proteins. One such MCA is called GLT-135, which is designed to recognize and bind to PTPN14. GLT-135 has been shown to be effective in preclinical studies in targeting PTPN14 and may be a potential therapeutic agent for GBM.

Measuring the effectiveness of PTPN14 inhibitors

To determine the effectiveness of PTPN14 inhibitors, researchers have used several different techniques, including cell-based assays, animal models, and clinical trials. One of the most commonly used techniques is cell-based assays, which involve the use of cells that have been genetically modified to express specific proteins, such as PTPN14.

In these cell-based assays, researchers will typically grown cells in culture and then treat the cells with different concentrations of the PTPN14 inhibitor. They will then measure the growth of the cells, as well as other factors, such as the expression of PTPN14, to determine the effectiveness of the inhibitor.

Another technique that can be used to measure the effectiveness of PTPN14 inhibitors is animal models. In these models, researchers will use animals that have been genetically modified to express specific proteins, such as PTPN14, and then treat the animals with different concentrations of the PTPN14 inhibitor. They will then measure the growth of the animals, as well as other factors, such as the expression of PTPN14, to determine the effectiveness of the inhibitor in animal models.

Finally, clinical trials can also be used to measure the effectiveness of PTPN14 inhibitors. In these trials, researchers will recruit patients with GBM and then treat them with different concentrations of the PTPN14 inhibitor. They will then measure the response of the tumors, as well as other factors, such as the expression of PTPN14, to determine the effectiveness of the inhibitor in clinical trials.

Conclusion

PTPN14 is a protein that has been shown to play a role in the development and progression of GBM. In addition,

Protein Name: Protein Tyrosine Phosphatase Non-receptor Type 14

Functions: Protein tyrosine phosphatase which may play a role in the regulation of lymphangiogenesis, cell-cell adhesion, cell-matrix adhesion, cell migration, cell growth and also regulates TGF-beta gene expression, thereby modulating epithelial-mesenchymal transition. Mediates beta-catenin dephosphorylation at adhesion junctions. Acts as a negative regulator of the oncogenic property of YAP, a downstream target of the hippo pathway, in a cell density-dependent manner. May function as a tumor suppressor

The "PTPN14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTPN14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets